Text Size

Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects

This study has been completed.
Sponsor:
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov Identifier:
NCT00868530
First received: March 19, 2009
Last updated: April 1, 2011
Last verified: April 2011
History of Changes
Results First Received: December 3, 2010  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Hemophilia A
Intervention: Biological: Xyntha

  Participant Flow
  Show Participant Flow


  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Xyntha Participants received on-demand treatments with Xyntha (which occurred each time a participant experienced bleeding episode during the active phase of the study) according to investigator’s prescription over a 6-month (calendar day) period. A single 50 International Unit (IU)/kg (+/-5 IU/kg) intravenous (IV) bolus infusion of Xyntha was given for recovery assessments.

Baseline Measures
    Xyntha  
Number of Participants  
[units: participants]
 		  53  
Age  
[units: Years]
Mean ± Standard Deviation 		  23.2  ± 10.0  
Gender  
[units: Participants]
 		 
Female     0  
Male     53  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Investigator Hemostatic Efficacy Assessment 8 Hours Post Infusion   [ Time Frame: 8 hours post infusion ]
  Show Outcome Measure 1

2.  Primary:   Investigator Hemostatic Efficacy Assessment 24 Hours Post Infusion   [ Time Frame: 24 hours post infusion ]
  Show Outcome Measure 2

3.  Primary:   Number of Participants With Factor VIII (FVIII) Inhibitor Development   [ Time Frame: Day 1 and Month 6 or Early Termination Visit ]
  Show Outcome Measure 3

4.  Secondary:   FVIII Recovery : Change From Baseline in FVIII Concentration   [ Time Frame: Day 1 and Month 6 or Early Termination Visit ]
  Show Outcome Measure 4

5.  Secondary:   Number of Participants With Less Than Expected Therapeutic Effect (LETE)   [ Time Frame: 24 hours after each of 2 successive infusion, up to 6 months ]
  Show Outcome Measure 5

6.  Secondary:   Number of Participants With Thrombosis Allergic-Type Reactions   [ Time Frame: Baseline up to 6 months ]
  Show Outcome Measure 6

7.  Secondary:   Number of Participants With Thrombosis   [ Time Frame: Baseline up to 6 months ]
  Show Outcome Measure 7

8.  Other Pre-specified:   Frequency of Xyntha Infusions Required Per Hemorrhage   [ Time Frame: Day 1 to Month 6 or Early Termination Visit ]
  Show Outcome Measure 8

9.  Other Pre-specified:   Average Dose of Xyntha Infusions Required Per Hemorrhage   [ Time Frame: Day 1 to Month 6 or Early Termination Visit ]
  Show Outcome Measure 9


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Pfizer ClinicalTrials.gov Call Center
Organization: Pfizer, Inc.
phone: 1-800-718-1021
e-mail: ClinicalTrials.gov_Inquiries@pfizer.com


No publications provided


Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc
ClinicalTrials.gov Identifier: NCT00868530     History of Changes
Other Study ID Numbers: 3082B2-3316, B1831015
Study First Received: March 19, 2009
Results First Received: December 3, 2010
Last Updated: April 1, 2011
Health Authority: China: Food and Drug Administration